FATE
HEALTHCAREFate Therapeutics Inc
AI Insight
What's Moving FATE Today?
No stock-specific AI insight has been generated for FATE yet. Check back soon — insights are generated from recent news analysis.
Market Briefings featuring FATE
52-Week Range
$0.91$2.88
$2.12
Fundamentals
Market Cap$251M
P/E Ratio—
EPS$-1.09
Dividend Yield—
Dividend / Share—
ROE-55.5%
Profit Margin—
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding116.6M
FATE News
28 articles- Director Laura Hamill files initial Form 3 for FATE Therapeutics (FATE)Stock Titan·Jun 16, 2026
- Fate Therapeutics Inc Stock (US3025491025): valuation focus as clinical-stage biotech trades near loAD HOC NEWS·Jun 15, 2026
- Fate Therapeutics Appoints Laura Hamill to Board of DirectorsYahoo Finance·Jun 15, 2026
- H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PTYahoo Finance·Jun 10, 2026
- Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6Moomoo·Jun 5, 2026
- Fate Therapeutics (NASDAQ: FATE) details FT819, FT836 data and cash runway into 2028Stock Titan·Jun 5, 2026
- Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual MeetingYahoo Finance·Jun 4, 2026
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 2, 2026
- Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual MeetingYahoo Finance·Jun 1, 2026
- Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely?Yahoo Finance·May 30, 2026
- Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune DiseasesYahoo Finance·May 21, 2026
- Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S ValuationSimply Wall Street·May 15, 2026
- Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 13, 2026
- Fate Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesYahoo Finance·May 13, 2026
- Fate Therapeutics Showcases FT819 Clinical Activity in SLEGlobeNewswire·May 12, 2026
- Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual MeetingYahoo Finance·May 11, 2026
- Fate Therapeutics (FATE) officer exercises 166,664 options, holds 609k sharesStock Titan·May 8, 2026
- CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseYahoo Finance·May 6, 2026
- Novavax (NVAX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819Yahoo Finance·May 5, 2026
- Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune DiseasesYahoo Finance·May 4, 2026
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 1, 2026
- Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 MeetingYahoo Finance·Apr 30, 2026
- Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual MeetingYahoo Finance·Apr 16, 2026
- Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham ConferenceMarketbeat·Apr 16, 2026
- Fate Therapeutics to Participate in Upcoming Second Quarter 2026 ConferencesYahoo Finance·Apr 9, 2026
- Scalable Biotech Manufacturing Unlocks a $14B MarketBenzinga·Mar 27, 2026
All 28 articles loaded
Price Data
Open$2.10
Previous Close$2.15
Day High$2.32
Day Low$2.10
52 Week High$2.88
52 Week Low$0.91
52-Week Range
$0.91$2.88
$2.12
Fundamentals
Market Cap$251M
P/E Ratio—
EPS$-1.09
Dividend Yield—
Dividend / Share—
ROE-55.5%
Profit Margin—
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding116.6M
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—